Asst Prof Wong Yien Ning Sophia

Dr Sophia Wong trained as a Medical Oncologist at University College London Hospital and Royal Free Hospital (London), with a PhD in Cancer Immunology from University College London, where she trained under Professor Sergio Quezada. After completing her specialist training in London, she pursued a post-training fellowship in solid cancer cellular therapy at the Royal Marsden Hospital (London) and the Netherlands Cancer Institute with Professor John Haanen. Her clinical and research focus is on translational immunotherapy, particularly in advancing cell therapies for solid tumours.

Dr Sophia started at the National Cancer Centre Singapore in 2024, where she  treated and led the first solid cancer cellular TIL therapy trial in Asia. She serves as Principal Investigator for ongoing clinical trials and has been awarded the NMRC Transition Award and STDR Grant to support her research in T cell therapy. Alongside her clinical and academic work, she remains actively involved in teaching and global oncology collaborations, with a goal to expand access to innovative therapies across Asia.

• PhD in Cancer Immunology, University College London 
• PG Cert in Oncology, Institute for Cancer Research 
• MRCP, Royal College of Physicians (London) 
• MBBS, King’s College London

• Assistant Professor, Duke-NUS Medical School

• NMRC Transition Award Singapore, 2025 
• ESMO Congress Travel Grant Award Switzerland, 2023 
• Association of Cancer Physicians (ACP) McElwain Prize (Translational) UK, 2021 •
• Sylvia Lawler Prize (Poster) UK, 2018 
• Experimental Cancer Medicine Centre Junior Investigator Network Group: Training the Next Generation Travel Grant Award UK, 2018 
• ESMO Congress Travel Grant Award UK, 2015 
• ESMO Congress Travel Grant Award Germany, 2013

• Cellular Therapy 
• Cancer Immunotherapy

• Julve M*, Wong YNS*, Lim KHJ, Furness AJS. Solid tumour cellular therapy–principles of toxicity management. Immuno-Oncology and Technology, Sep 2024; 100737 
• Davis L, Miller RE, Wong YNS*. The Landscape of Adoptive Cellular Therapies in Ovari-an Cancer. Cancers 2023; 15 (19), 4814 
• Vesely C*, Wong YNS* … et al, Tim Meyer. Systematic Evaluation of the Immune Envi-ronment of Small Intestinal Neuroendocrine Tumours. Clin Cancer Res. 2022 Mar 23;clincanres.4203.2021 
• Wong YNS*, Sng CCT* … et al, Roylance R, Shaw H, Lee AJX. Systemic Anti-Cancer Therapy and Metastatic Cancer Are Independent Mortality Risk Factors during Two UK Waves of the COVID-19 Pandemic at University College London Hospital. Cancers (Ba-sel). 2021 Dec 2;13(23):6085 
• Sng CCT*, Wong YNS* … et al, Roylance R, Lee AJX, Shaw H. Cancer History and Sys-temic Anti-Cancer Therapy Independently Predict COVID-19 Mortality: A UK Tertiary Hos-pital Experience. Front. Oncol. 20 November 2020 
• Pinato DJ, … Wong YNS, et al, Tabernero J, Gennari A. Clinical portrait of the SARS-CoV-2 epidemic in European cancer patients. Cancer Discov. 2020 Jul 31:CD-20-0773 
• Wong YNS, … et al, Linch MD, Quezada SA. Urine-derived lymphocytes as a non-invasive measure of the bladder tumor immune microenvironment. J Exp Med. 2018 Nov 5;215(11):2748-2759 
• Arce Vargas F, … Wong YNS, et al. Fc effector function contributes to the activity of hu-man anti-CTLA-4 antibodies. Cancer Cell. 2018 Apr 9;33(4):649-663.e4. 
• Wong YNS, Joshi K, Pule M, Peggs KS, Swanton C, Quezada SA, Linch M. Evolving adoptive cellular therapies in urological malignancies. Lancet Oncol. 2017 Jun;18(6):e341-e353 
• Turajlic S, … Wong YNS, et al, Quezada SA, Swanton C. Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis. Lan-cet Oncol. 2017 Jul 7. pii: S1470-2045(17)30516-8 
• Jamal-Hanjani M et al… TRACERx Consortium (Wong YNS). Tracking the Evolution of Non-Small-Cell Lung Cancer. N Engl J Med. 2017 Jun 1;376(22):2109-2121 
• Linch M, … Wong YNS, et al, Swanton C. Intratumoural evolutionary landscape of high-risk prostate cancer: the PROGENY study of genomic and immune parameters. Annals of Oncology. 2017 Oct 1;28(10):2472-2480 
• Wong YNS, Ferraldeschi R, Attard G and de Bono JS. Evolution of androgen receptor tar-geted therapy for advanced prostate cancer. Nature Reviews Clinical Oncology. 2014;11(6):365-76 
• Wong YNS, Jack RH, Mak V, Møller H and Davies EA. The epidemiology and survival of extrapulmonary small cell carcinoma in South East England, 1970-2004. BMC Cancer. 2009; 9:209 
• Holmberg L, Wong YNS, … et al. Mammography casting-type calcification and risk of local recurrence in DCIS: analyses from a randomised study. British Journal of Cancer. 2013; 108